Class information for:
Level 1: RAS DERIVED PEPTIDES//P53 PEPTIDES//RAS PEPTIDES

Basic class information
Class id #P Avg. number of
references		 Database coverage
of references
26564 251 41.8 92%


Bar chart of Publication_year

Last years might be incomplete

Hierarchy of classes
The table includes all classes above and classes immediately below the current class.


Cluster id Level Cluster label #P
0 4 BIOCHEMISTRY & MOLECULAR BIOLOGY//CELL BIOLOGY//ONCOLOGY 4064930
10 3       IMMUNOLOGY//JOURNAL OF IMMUNOLOGY//IMMUNOL 134299
140 2             IMMUNOTHERAPY//DENDRITIC CELLS//CANCER IMMUNOLOGY IMMUNOTHERAPY 23462
26564 1                   RAS DERIVED PEPTIDES//P53 PEPTIDES//RAS PEPTIDES 251

Terms with highest relevance score


rank Term termType Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 RAS DERIVED PEPTIDES authKW 486619 2% 100% 4
2 P53 PEPTIDES authKW 364964 1% 100% 3
3 RAS PEPTIDES authKW 324410 2% 67% 4
4 MUTANT P21 RAS authKW 273722 1% 75% 3
5 DEPOVAX authKW 243309 1% 100% 2
6 MUTATED RAS P21 authKW 243309 1% 100% 2
7 P53 EPITOPES authKW 243309 1% 100% 2
8 PEPTIDE MAJOR HISTOCOMPATIBILITY COMPLEX AFFINITY authKW 243309 1% 100% 2
9 ANTI SELF authKW 121655 0% 100% 1
10 ASSOCIE 9 COMITE PARIS LIGUE CONTRE CANC address 121655 0% 100% 1

Web of Science journal categories


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 Immunology 2637 49% 0% 123
2 Oncology 2371 50% 0% 126
3 Medicine, Research & Experimental 532 18% 0% 45
4 Biotechnology & Applied Microbiology 19 5% 0% 13
5 Genetics & Heredity 9 4% 0% 10
6 Cell Biology 6 5% 0% 12
7 Hematology 3 2% 0% 5
8 Dermatology 2 1% 0% 3
9 Gastroenterology & Hepatology 1 2% 0% 4
10 Transplantation 1 1% 0% 2

Address terms


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 ASSOCIE 9 COMITE PARIS LIGUE CONTRE CANC 121655 0% 100% 1
2 CANC ETIOL OUTCOMES 121655 0% 100% 1
3 COMITE PARIS LIGUE CONTRE CANC ASSOCIE 9 121655 0% 100% 1
4 CONCEPT PLICAT MOL BIOACTIVEQUIPE BIOVEC 121655 0% 100% 1
5 DIAGNOST MOL PATHOL SERV 121655 0% 100% 1
6 IMMUNOL IMM15 121655 0% 100% 1
7 IMPCL 121655 0% 100% 1
8 LUACR 121655 0% 100% 1
9 MASSACHUSETTS GEN HOSPCMI TRANSPLANTAT UNIT 121655 0% 100% 1
10 MED OTOLARYNGOL IMMUNOL 121655 0% 100% 1

Journals


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 CANCER IMMUNOLOGY IMMUNOTHERAPY 7162 6% 0% 16
2 JOURNAL OF IMMUNOTHERAPY 3534 3% 0% 7
3 INTERNATIONAL JOURNAL OF CANCER 2400 8% 0% 20
4 ONCOIMMUNOLOGY 2030 2% 0% 4
5 EUROPEAN JOURNAL OF IMMUNOLOGY 1803 6% 0% 14
6 CLINICAL CANCER RESEARCH 1372 5% 0% 13
7 JOURNAL OF TRANSLATIONAL MEDICINE 1306 2% 0% 5
8 PORTLAND PRESS PROCEEDINGS 1265 0% 1% 1
9 CANCER IMMUNOLOGY RESEARCH 1080 1% 0% 2
10 CELLULAR IMMUNOLOGY 988 3% 0% 8

Author Key Words


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class		 LCSH search Wikipedia search
1 RAS DERIVED PEPTIDES 486619 2% 100% 4 Search RAS+DERIVED+PEPTIDES Search RAS+DERIVED+PEPTIDES
2 P53 PEPTIDES 364964 1% 100% 3 Search P53+PEPTIDES Search P53+PEPTIDES
3 RAS PEPTIDES 324410 2% 67% 4 Search RAS+PEPTIDES Search RAS+PEPTIDES
4 MUTANT P21 RAS 273722 1% 75% 3 Search MUTANT+P21+RAS Search MUTANT+P21+RAS
5 DEPOVAX 243309 1% 100% 2 Search DEPOVAX Search DEPOVAX
6 MUTATED RAS P21 243309 1% 100% 2 Search MUTATED+RAS+P21 Search MUTATED+RAS+P21
7 P53 EPITOPES 243309 1% 100% 2 Search P53+EPITOPES Search P53+EPITOPES
8 PEPTIDE MAJOR HISTOCOMPATIBILITY COMPLEX AFFINITY 243309 1% 100% 2 Search PEPTIDE+MAJOR+HISTOCOMPATIBILITY+COMPLEX+AFFINITY Search PEPTIDE+MAJOR+HISTOCOMPATIBILITY+COMPLEX+AFFINITY
9 ANTI SELF 121655 0% 100% 1 Search ANTI+SELF Search ANTI+SELF
10 CANCER PRONE MICE 121655 0% 100% 1 Search CANCER+PRONE+MICE Search CANCER+PRONE+MICE

Core articles
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c:
(1) Number of references referring to publications in the class.
(2) Share of total number of active references referring to publications in the class.
(3) Age of the article. New articles get higher score than old articles.
(4) Citation rate, normalized to year.


Rank Reference # ref.
in cl.		 Shr. of ref. in
cl.		 Citations
1 DELEO, AB , WHITESIDE, TL , (2008) DEVELOPMENT OF MULTI-EPITOPE VACCINES TARGETING WILD-TYPE-SEQUENCE P53 PEPTIDES.EXPERT REVIEW OF VACCINES. VOL. 7. ISSUE 7. P. 1031-1040 31 58% 8
2 BLACK, APB , OGG, GS , (2003) THE ROLE OF P53 IN THE IMMUNOBIOLOGY OF CUTANEOUS SQUAMOUS CELL CARCINOMA.CLINICAL AND EXPERIMENTAL IMMUNOLOGY. VOL. 132. ISSUE 3. P. 379-384 40 48% 8
3 NIJMAN, HW , LAMBECK, A , VAN DER BURG, SH , VAN DER ZEE, AGJ , DAEMEN, T , (2005) IMMUNOLOGIC ASPECT OF OVARIAN CANCER AND P53 AS TUMOR ANTIGEN.JOURNAL OF TRANSLATIONAL MEDICINE. VOL. 3. ISSUE . P. 1 -12 51 34% 18
4 BLACK, AP , BAILEY, A , JONES, L , TURNER, RJ , HOLLOWOOD, K , OGG, GS , (2005) P53-SPECIFIC CD8+T-CELL RESPONSES IN INDIVIDUALS WITH CUTANEOUS SQUAMOUS CELL CARCINOMA.BRITISH JOURNAL OF DERMATOLOGY. VOL. 153. ISSUE 5. P. 987-991 21 72% 10
5 FERRIES, E , CONNAN, F , PAGES, F , GASTON, J , HAGNERE, AM , VIEILLEFOND, A , THIOUNN, N , GUILLET, JG , CHOPPIN, J , (2001) IDENTIFICATION OF P53 PEPTIDES RECOGNIZED BY CD8(+) T LYMPHOCYTES FROM PATIENTS WITH BLADDER CANCER.HUMAN IMMUNOLOGY. VOL. 62. ISSUE 8. P. 791-798 25 68% 19
6 SONG, GY , SRIVASTAVA, T , ISHIZAKI, H , LACEY, SF , DIAMOND, DJ , ELLENHORN, JDI , (2011) RECOMBINANT MODIFIED VACCINIA VIRUS ANKARA (MVA) EXPRESSING WILD-TYPE HUMAN P53 INDUCES SPECIFIC ANTITUMOR CTL EXPANSION.CANCER INVESTIGATION. VOL. 29. ISSUE 8. P. 501 -510 23 49% 5
7 SPEETJENS, FM , KUPPEN, PK , WELTERS, MJP , ESSAHSAH, F , VAN DEN BRINK, AMEGV , LANTRUA, MGK , VALENTIJN, ARPM , OOSTENDORP, J , FATHERS, LM , NIJMAN, HW , ET AL (2009) INDUCTION OF P53-SPECIFIC IMMUNITY BY A P53 SYNTHETIC LONG PEPTIDE VACCINE IN PATIENTS TREATED FOR METASTATIC COLORECTAL CANCER.CLINICAL CANCER RESEARCH. VOL. 15. ISSUE 3. P. 1086-1095 22 47% 56
8 SAKAKURA, K , CHIKAMATSU, K , FURUYA, N , APPELLA, E , WHITESIDE, TL , DELEO, AB , (2007) TOWARD THE DEVELOPMENT OF MULTI-EPITOPE P53 CANCER VACCINES: AN IN VITRO ASSESSMENT OF CD8(+) T CELL RESPONSES TO HLA CLASS I-RESTRICTED WILD-TYPE SEQUENCE P53 PEPTIDES.CLINICAL IMMUNOLOGY. VOL. 125. ISSUE 1. P. 43-51 19 51% 11
9 LAMBECK, A , LEFFERS, N , HOOGEBOOM, BN , SLUITER, W , HAMMING, I , KLIP, H , TEN HOOR, K , ESAJAS, M , VAN OVEN, M , DRIJFHOUT, JW , ET AL (2007) P53-SPECIFIC T CELL RESPONSES IN PATIENTS WITH MALIGNANT AND BENIGN OVARIAN TUMORS: IMPLICATIONS FOR P53 BASED IMMUNOTHERAPY.INTERNATIONAL JOURNAL OF CANCER. VOL. 121. ISSUE 3. P. 606-614 23 41% 15
10 PEDERSEN, AE , STRYHN, A , JUSTESEN, S , HARNDAHL, M , RASMUSSEN, S , DONSKOV, F , CLAESSON, MH , PEDERSEN, JW , WANDALL, HH , SVANE, IM , ET AL (2011) WILDTYPE P53-SPECIFIC ANTIBODY AND T-CELL RESPONSES IN CANCER PATIENTS.JOURNAL OF IMMUNOTHERAPY. VOL. 34. ISSUE 9. P. 629-640 16 50% 4

Classes with closest relation at Level 1


Rank Class id link
1 1375 CANCER TESTIS ANTIGEN//NY ESO 1//MAGE
2 16780 CANC VACCINE DEV PROGRAM//CANC IMMUNOL IMMUNOTHER Y//TUMOR VACCINE GRP
3 12484 ANTI P53 ANTIBODIES//SERUM P53 ANTIBODY//P53 ANTIBODIES
4 13629 TUMOR IMMUNOL BIOL//SIPULEUCEL T//5T4
5 25112 GV1001//PA MSHA VACCINE//HTERTC27
6 24733 TUMOR IMMUN TOLERANCE SECT//SV40 T ANTIGEN TRANSGENIC MICE//CCDC134
7 24888 CANC VACCINE DEV//INNOVAT CANC THER Y//PERSONALIZED PEPTIDE VACCINE
8 2264 TAPASIN//TRANSPORTER ASSOCIATED WITH ANTIGEN PROCESSING//PEPTIDE LOADING COMPLEX
9 643 DENDRITIC CELLS//IMMUNOTHERAPY//TUMOR LYSATE
10 25218 ORAL BIOL ORAL MED//CD3 ZETA//ZETA CHAIN

Go to start page